Materials characterisation part II: tip geometry of the Vickers indenter for microindentation tests

This is the second of two papers by the authors associated with materials characterisation methods based on hardness testing. It is important to have knowledge of the tip geometry of the indenter employed in the hardness test as this affects the correctness of the value of contact area parameter used to determine the mechanical properties. In this paper, outcomes of a study concerned with the tip geometry of the Vickers microindenter are presented. Results from experiment are compared with results from published works and the most current accepted analytical models. A new non-contact methodology based on a residual imprint imaging process is developed and further compared with other methods using experimental and numerical analyses over a wide range of material properties. For confirmation, an assessment was undertaken using numerical dimensional analysis which permitted a large range of materials to be explored. It is shown that the proposed method is more accurate compared with other methods regardless of the mechanical properties of the material. The outcomes demonstrate that measuring contact area with the new method enhanced the overall relative error in the resulting mechanical properties including hardness and Young’s modulus of elasticity. It is also shown that the value of the contact area using actual indenter geometry obtained from experimental load-displacement analysis or FEM numerical analysis is more accurate than the value obtained from the assumption of perfect indenter geometry and hence can be used for materials with low strain hardening property. © 2017 Springer-Verlag Londo

Filgotinib suppresses HIV-1–driven gene transcription by inhibiting HIV-1 splicing and T cell activation

Despite effective antiretroviral therapy, HIV-1-infected cells continue to produce viral antigens and induce chronic immune exhaustion. We propose to identify HIV-1-suppressing agents that can inhibit HIV-1 reactivation and reduce HIV-1-induced immune activation. Using a newly developed dual-reporter system and a high-throughput drug screen, we identified FDA-approved drugs that can suppress HIV-1 reactivation in both cell line models and CD4+ T cells from virally suppressed HIV-1-infected individuals. We identified 11 cellular pathways required for HIV-1 reactivation as druggable targets. Using differential expression analysis, gene set enrichment analysis, and exon-intron landscape analysis, we examined the impact of drug treatment on the cellular environment at a genome-wide level. We identified what we believe to be a new function of a JAK inhibitor, filgotinib, that suppresses HIV-1 splicing. First, filgotinib preferentially suppresses spliced HIV-1 RNA transcription. Second, filgotinib suppresses HIV-1-driven aberrant cancer-related gene expression at the integration site. Third, we found that filgotinib suppresses HIV-1 transcription by inhibiting T cell activation and by modulating RNA splicing. Finally, we found that filgotinib treatment reduces the proliferation of HIV-1-infected cells. Overall, the combination of a drug screen and transcriptome analysis provides systematic understanding of cellular targets required for HIV-1 reactivation and drug candidates that may reduce HIV-1-related immune activation